Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque

Magnetic Resonance in Medicine

Volumn 62, Issue 5, 2009, Pages 1195-1201

  Beilvert, Anne ^a,b,c   Cormode, David P ^b   Chaubet, Frédéric ^a,d   Briley Saebo, Karen C ^b   Mani, Venkatesh ^b   Mulder, Willem J M ^b   Vucic, Esad ^b   Toussaint, Jean François ^c   Letourneur, Didier ^a,d   Fayad, Zahi A ^b  

^a INSERM   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

Atherosclerosis; Contrast agent; Lipid core; Micelle; MRI

Indexed keywords

ALIPHATIC COMPOUNDS; AMINO ACIDS; BLOOD VESSELS; DISEASES; FLUORESCENCE MICROSCOPY; LIPOPROTEINS; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MAMMALS; POLYETHYLENE GLYCOLS; POLYETHYLENES;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTRAST AGENT; DIETHYLENETRIAMINE PENTA-ACETIC ACIDS; HISTOLOGICAL SECTION; LIPID CORES; MAGNETIC RESONANCE CONTRAST AGENTS; MR CONTRAST AGENTS;

MICELLES;

AMPHOPHILE; APOLIPOPROTEIN E; AROMATIC AMINO ACID; CONTRAST MEDIUM; GADOLINIUM PENTETATE; LIPID; LIPOPROTEIN; MACROGOL; TYROSINE MACROGOL; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; LIPID ANALYSIS; MALE; MICELLE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 70449440597     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22103     Document Type: Article

References (45)

1. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2008;51:944-955.
2. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-1844. (Pubitemid 350287108)
3. Honda M, Kawahara I, Kitagawa N, Tsutsumi K, Morikawa M, Hayashi T, Nagata I. Asymptomatic carotid artery plaques: use of magnetic resonance imaging to characterize vulnerable plaques in 6 cases. Surg Neurol 2007;67:35-39. (Pubitemid 46038500)
4. Trivedi RA, U King-Im JM, Graves MJ, Horsley J, Goddard M, Kirkpatrick PJ, Gillard JH. MRI-derived measurements of fibrous-cap and lipid-core thickness: the potential for identifying vulnerable carotid plaques in vivo. Neuroradiology 2004;46:738-743. (Pubitemid 39294893)
5. Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, Weinmann HJ, Fuster V, Toussaint JF, Fayad ZA. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 2004;109:2890-2896. (Pubitemid 38780304)
6. Meding J, Urich M, Licha K, Reinhardt M, Misselwitz B, Fayad ZA, Weinmann HJ. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast Media Mol Imaging 2007;2:120-129. (Pubitemid 47180344)
7. Aime S, Botta M, Terreno E. Gd(III)-based contrast agents for MRI. Advances in Inorganic Chemistry, Vol.57. Academic Press; 2005. p 173-237.
8. Broz P, Marsch S, Hunziker P. Targeting of vulnerable plaque macrophages with polymer-based nanostructures. Trends Cardiovasc Med 2007;17:190-196. (Pubitemid 47089008)
9. Lattuada L, Lux G. Synthesis of Gd-DTPA-cholesterol: a new lipophilic gadolinium complex as a potential MRI contrast agent. Tetrahedron Lett 2003;44:3893-3895. (Pubitemid 36513798)
10. Yu G, Yamashita M, Aoshima K, Takahashi M, Oshikawa T, Takayanagi H, Laurent S, Burtea C, Vander Elst L, Muller RN. A glycosylated complex of gadolinium, a new potential contrast agent for magnetic resonance angiography? Bioorg Med Chem Lett 2007;17:2246-2249.
11. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
12. Datta G, Epand RF, Epand RM, Chaddha M, Kirksey MA, Garber DW, Lund-Katz S, Phillips MC, Hama S, Navab M, Fogelman AM, Palgunachari MN, Segrest JP, Anantharamaiah GM. Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem 2004;279:26509-26517. (Pubitemid 38798805)
13. Shah PK, Chyu KY. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 2005;15:291-296.
14. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, Segrest JP. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 1985;260:10248-10255. (Pubitemid 16246560)
15. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005;25:1325-1331.
16. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA 2007;104:961-966. (Pubitemid 46154719)
17. van Tilborg GA, Mulder WJ, Deckers N, Storm G, Reutelingsperger CP, Strijkers GJ, Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem 2006;17:741-749. (Pubitemid 43794385)
18. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2103-2109.
19. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 2005;102:17757-17762. (Pubitemid 41803570)
20. Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JG, Vucic E, Amirbekian V, Tang C, Chin PT, Nicolay K, Fayad ZA. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007;58:1164-1170. (Pubitemid 350234203)
21. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001;73:137-172. (Pubitemid 32544594)
22. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004;56:1273-1289.
23. Torchilin VP. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 2000;1:183-215.
24. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004;55:503-517.
25. Briley-Saebo KC, Amirbekian V, Mani V, Aguinaldo JG, Vucic E, Carpenter D, Amirbekian S, Fayad ZA. Gadolinium mixed-micelles: effect of the amphiphile on in vitro and in vivo efficacy in apolipoprotein E knockout mouse models of atherosclerosis. Magn Reson Med 2006;56:1336-1346. (Pubitemid 44865316)
26. Van Butsele K, Sibret P, Fustin CA, Gohy JF, Passirani C, Benoit JP, Jerome R, Jerome C. Synthesis and pH-dependent micellization of diblock copolymer mixtures. J Colloid Interface Sci 2009;329:235-243.
27. Briley-Saebo KC, Shaw PX, Mulder WJM, Choi S-H, Vucic E, Aguinaldo JGS, Witztum JL, Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008;117:3206-3215.
28. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-140. (Pubitemid 24028177)
29. Lukyanov AN, Gao Z, Torchilin VP. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 2003;91:97-102. (Pubitemid 37288880)
30. Rodriguez-Lee M, Bondjers G, Camejo G. Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans. Curr Opin Lipidol 2007;18:546-553. (Pubitemid 47462208)
31. Fischer JW, Steitz SA, Johnson PY, Burke A, Kolodgie F, Virmani R, Giachelli C, Wight TN. Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:2391-2396. (Pubitemid 39658047)
32. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007;27:1159-1165. (Pubitemid 46641972)
33. Saam T, Ferguson MS, Yarnykh VL, Takaya N, Xu D, Polissar NL, Hatsukami TS, Yuan C. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol 2005;25:234-239. (Pubitemid 40054282)
34. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, Small R, Davies JW, Kerwin WS, Hatsukami TS. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001;104:2051-2056.
35. Toussaint J-F, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996;94:932-938. (Pubitemid 26292843)
36. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the committee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
37. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47(8 Suppl 1):C13-C18.
38. Wasserman BA, Sharrett AR, Lai S, Gomes AS, Cushman M, Folsom AR, Bild DE, Kronmal RA, Sinha S, Bluemke DA. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the Multi-Ethnic Study of Atherosclerosis (MESA). Stroke 2008;39:329-335. (Pubitemid 351619451)
39. Lee JMS, Choudhury RP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart 2007;93:559-564.
40. Lee JMS, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, Francis JM, Jackson CE, Robson MD, Neubauer S, Channon KM, Choudhury RP. Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging. Atherosclerosis 2008;197:951-958.
41. Zhao X-Q, Yuan C, Hatsukami TS, Frechette EH, Kang X-J, Maravilla KR, Brown BG. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001;21:1623-1629. (Pubitemid 34215582)
42. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:249-252. (Pubitemid 32666942)
43. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 2006;6:2220-2224. (Pubitemid 44663808)
44. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750-754. (Pubitemid 34640629)
45. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003;107:2068-2071.